Indivior · ISIN: GB00BN4HT335

Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained

SLOUGH, United Kingdom and RICHMOND, Va., July 25, 2025 /PRNewswire/ -- Further to the announcement made on June 2, 2025, Indivior PLC (Nasdaq: INDV) today announces that: (i) the secondary listing of the Company's Ordinary Shares ("Ordinary Shares") on the Equity Shares (Transition) category of the Official List of the UK Financial Conduct Autho...

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

This news feed is a compilation of company-relevant news from the most popular and widest-reaching newswire services. The feed is updated several times. For market-related publications, we recommend the X-Billboard, the Daily News Digest or our Premium Information Service.
Most recent update: 25.07.2025 | 08:00
25 July 2025 08:00AM
Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained
SLOUGH, United Kingdom and RICHMOND, Va., July 25, 2025 /PRNewswire/ -- Further to the announcement made on June 2, 2025, Indivior PLC (Nasdaq: INDV) today announces that: (i) the secondary listing of the Company's Ordinary Shares ("Ordinary Shares") on the Equity Shares (Transition) category of the Official List of the UK Financial Conduct Autho...
Indivior
© PR Newswire
23 July 2025 02:00PM
Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid Use Disorder
Extended-release buprenorphine (BUP-XR) had lower rates of hospitalizations, emergency department (ED) visits, and outpatient physician office visits compared to those receiving daily oral buprenorphine or no medications for opioid use disorder (MOUD)The study indicates BUP-XR may be an important tool in reducing ED visits, improving healthcare res...
Indivior
© PR Newswire
17 July 2025 03:00PM
Indivior to Report Second Quarter 2025 Financial Results and Host Webcast on July 31st
RICHMOND, Va., July 17, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced that it will report second quarter 2025 financial results on Thursday, July 31, 2025 at 7:00 a.m. U.S. ET.  Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior's leadership team will host...
Indivior
© PR Newswire
08 July 2025 02:00PM
Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs
RICHMOND, Va., July 8, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Vanessa Procter as Executive Vice President of Corporate Affairs, effective July 7, 2025. Vanessa is a seasoned corporate affairs leader with extensive experience in the biopharmaceutical industry, and will be responsible for Corporate...
Indivior
© PR Newswire
30 June 2025 01:00PM
Indivior Announces Inclusion in the U.S. Russell 2000® and 3000® Indexes
RICHMOND, Va., June 30, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) will be added as a member of the U.S. small-cap Russell 2000® Index, effective after the U.S. market opens today as part of the 2025 Russell indexes reconstitution. The annual reconstitution of the Russell U.S. indexes captures the 4,000 largest U.S. stocks as of April...
Indivior
© PR Newswire
24 June 2025 10:12PM
Indivior Appoints Tony Kingsley to the Board of Directors
RICHMOND, Va., June 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Tony Kingsley to the Board of Directors as an Independent Non-Executive Director, effective July 1, 2025. Mr. Kingsley was appointed pursuant to Indivior's relationship agreement with affiliates of Oaktree Capital Management, L.P., wh...
Indivior
© PR Newswire
19 June 2025 03:00PM
Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users
A post-hoc analysis demonstrates that buprenorphine exposure with 300 mg SUBLOCADE® (buprenorphine extended-release) may improve treatment outcomes among opioid use disorder (OUD) patients with heavy fentanyl use1Additional Indivior-funded research identified OUD treatment barriers in American Indian/Alaska Native (AI/AN) people who are often aff...
Indivior
© PR Newswire
02 June 2025 08:00AM
Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained
SLOUGH, England and RICHMOND, Va., June 2, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its intention to cancel: (i) the secondary listing of the Company's Ordinary Shares ("Ordinary Shares") on the Equity Shares (Transition) category of the Official List (the "Official List") of the U.K. Financial Conduct Authority ("FCA"...
Indivior
© PR Newswire
27 May 2025 02:30PM
Indivior Announces Patrick Barry as Chief Commercial Officer
Seasoned commercial executive with more than 30 years of pharmaceutical experience RICHMOND, Va., May 27, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the appointment of Patrick Barry as Chief Commercial Officer, effective June 2. In this role, Barry will lead the company's commercial growth strategy, execution, and operat...
Indivior
© PR Newswire
13 May 2025 04:00PM
Indivior to Participate in Upcoming Investor Events
RICHMOND, Va., May 13, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ/LSE: INDV) today announced that it will participate in the following investor events: Jefferies Global Healthcare Conference – New York City, NYJoe Ciaffoni, Chief Ex...
Indivior
© PR Newswire
01 May 2025 04:27PM
New Study Highlights Monthly SUBLOCADE® as a Potential Treatment Option for Opioid Use Disorder During and After Pregnancy
SUBLOCADE use during pregnancy showed no increased risk of birth defects, miscarriage, or maternal complications compared to general population rates RICHMOND, Va., May 1, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the publication of a study "Monthly Buprenorphine Depot Injection (SUBLOCADE) for Opioid Use Disorder Durin...
Indivior
© PR Newswire
24 April 2025 08:00AM
Indivior Announces Q1 2025 Financial Results
SLOUGH, United Kingdom and RICHMOND, Va., April 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending March 31, 2025. The earnings release, investor presentation and webcast are available at www.indivior.com....
Indivior
© PR Newswire
04 March 2025 02:40PM
Indivior Announces Further Changes to Board of Directors
RICHMOND, Va., March 4, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ / LSE: INDV) ("Indivior" or the "Company") today announced that, further to the announcement on December 17, 2024 of certain Director arrangements agreed with Oaktree Capital Management L.P. ("Oaktree"), the announcement on January 28, 2025 of the appointment of Dr. David Wheadon a...
Indivior
© PR Newswire
27 February 2025 08:00AM
Indivior Announces Joseph Ciaffoni Appointed Chief Executive Officer
RICHMOND, Va., Feb. 27, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) has appointed Joe Ciaffoni, currently an Independent Non-Executive Director of the Company, as Chief Executive Officer. The terms of his appointment are subject to, and effective upon, the approval by shareholders of a new remuneration policy at the Company's AGM in May...
Indivior
© PR Newswire
24 February 2025 08:00AM
Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection
Rapid Initiation Protocol Reduces Time to Treatment with SUBLOCADE® From One Week to One Hour, A Significant Advancement in the Treatment of Moderate to Severe Opioid Use Disorder (OUD) RICHMOND, Va., Feb. 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV), a global leader in addiction treatment, today announced that the U.S. Food and Drug...
Indivior
© PR Newswire
20 February 2025 08:00AM
Indivior Announces FY and Q4 2024 Financial Results
SLOUGH, United Kingdom and RICHMOND, Va., Feb. 20, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending December 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com....
Indivior
© PR Newswire
12 February 2025 08:00AM
Indivior Statement RE: Delayed FDA Approval of SUBLOCADE® Label Changes
RICHMOND, Va., Feb. 12, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) provides the following update regarding its PDUFA action date for label changes (rapid initiation protocol and alternative injection sites) for SUBLOCADE® (buprenorphine extended-release) Injection, which was scheduled for February 7, 2025:...
Indivior
© PR Newswire
19 November 2024 06:52PM
Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024
Data show rapid initiation with once-monthly SUBLOCADE significantly improves retention in opioid use disorder (OUD) patients, especially among fentanyl-positive participants. Study also administered second SUBLOCADE injection a week later vs. standard 28 days, enabling patients to achieve and maintain target medication levels more quickly.Presen...
Indivior
© PR Newswire
07 November 2024 08:24PM
Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior
RICHMOND, Va., Nov. 7, 2024 /PRNewswire/ -- Indivior PLC (NASDAQ / LSE: INDV) the Board of Directors (the "Board") of Indivior plc ("Indivior" or the "Company") notes the publication today of a letter from Oaktree Capital Management LP ("Oaktree") to the Board of Indivior....
Indivior
© PR Newswire
30 October 2024 05:30PM
Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month
Evidence demonstrates that SUBLOCADE supports long-term recovery from opioid use disorder (OUD) and is effective and safe.Publications highlight the importance of overcoming access barriers to long-acting injectable treatments for OUDRICHMOND, Va., Oct. 30, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV), in recognizing Substance Abuse Preve...
Indivior
© PR Newswire
24 October 2024 08:00AM
Indivior Announces Q3 2024 Financial Results
SLOUGH, United Kingdom and RICHMOND, Va., Oct. 24, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending September 30, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com....
Indivior
© PR Newswire
24 October 2024 08:00AM
Indivior Announces Q3 2024 Financial Results
SLOUGH, United Kingdom and RICHMOND, Va., Oct. 24, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending September 30, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at www.indivior.com/investorsThe inves...
Indivior
© PR Newswire
10 October 2024 01:00PM
Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion
Conference Call Today at 8:00 AM US Eastern THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018). RICHMOND, Va., Oct. 10, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today...
Indivior
© PR Newswire
10 October 2024 01:00PM
Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion
Conference Call Today at 8:00 AM US Eastern THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018). RICHMOND, Va., Oct. 10, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today...
Indivior
© PR Newswire
07 October 2024 05:30PM
Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review
PDUFA date set for February 7, 2025If approved by the FDA, label would expand to include alternative injection sites in the thigh, buttock and back of the arm for induction and maintenance as well as rapid induction one hour after a single transmucosal buprenorphine dose; both of which address significant patient and healthcare provider unmet nee...
Indivior
© PR Newswire
01 October 2024 04:20PM
INDV Investors Have Opportunity to Lead Indivior PLC Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Indivior PLC (“Indivior” or “the Company”) (NASDAQ: INDV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors...
Indivior
© BusinessWire
30 September 2024 06:00PM
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Indivior PLC (INDV)
The Law Offices of Frank R. Cruz reminds investors of the upcoming October 1, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Indivior PLC (“Indivior” or the “Company”) (NASDAQ: INDV) securities between February 22, 2024 and July 8, 2024, inclusive (the “Class Period”). If you are a shar...
Indivior
© BusinessWire
30 September 2024 02:45PM
INDV Investors Have Opportunity to Lead Indivior PLC Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, Sept. 30, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Indivior PLC ("Indivior" or "the Company") (NASDAQ: INDV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. S...
Indivior
© PR Newswire
30 September 2024 11:45AM
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Indivior PLC(INDV) Shareholders
NEW YORK, Sept. 30, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Indivior PLC (NASDAQ: INDV). Shareholders who purchased shares of INDV during the class period listed are encouraged to cont...
Indivior
© PR Newswire
30 September 2024 12:01AM
INDV Deadline: Rosen Law Firm Urges Indivior PLC (INDV) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers and acquirers of securities of Indivior PLC (NASDAQ: INDV) between February 22, 2024 and July 8, 2024, both dates inclusive (the “Class Period”). Indivior PLC is a pharmaceutical company. For more information, submi...
Indivior
© BusinessWire
28 September 2024 03:30AM
INDV Deadline: INDV Investors Have Opportunity to Lead Indivior PLC Securities Fraud Lawsuit
NEW YORK, Sept. 27, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers and acquirers of securities of Indivior PLC (NASDAQ: INDV) between February 22, 2024 and July 8, 2024, both dates inclusive (the "Class Period"), of the important October 1, 2024 lead plaintiff deadline....
Indivior
© PR Newswire
27 September 2024 10:12PM
INDV Investors Have Opportunity to Lead Indivior PLC Securities Fraud Lawsuit
BENSALEM, Pa., Sept. 27, 2024 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Indivior PLC ("Indivior" or the "Company") (NASDAQ: INDV). Class Period: February 22, 2024 – July 8, 2024Lead Plaintiff Deadline: October 1, 2024...
Indivior
© PR Newswire
27 September 2024 11:45AM
Shareholders that lost money on Indivior PLC(INDV) should contact Levi & Korsinsky about pending Class Action - INDV
NEW YORK, Sept. 27, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Indivior PLC ("Indivior" or the "Company") (NASDAQ: INDV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover...
Indivior
© PR Newswire
26 September 2024 11:45AM
Indivior PLC Sued for Securities Law Violations - Contact The Gross Law Firm Before October 1, 2024 to Discuss Your Rights - INDV
NEW YORK, Sept. 26, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Indivior PLC (NASDAQ: INDV). Shareholders who purchased shares of INDV during the class period listed are encouraged to cont...
Indivior
© PR Newswire
25 September 2024 04:00PM
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Indivior PLC of Class Action Lawsuit and Upcoming Deadlines - INDV
NEW YORK, Sept. 25, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Indivior PLC ("Indivior" or the "Company") (NASDAQ: INDV) and certain officers. The class action, filed in the United States District Court for the Eastern District of Virginia (Richmond Division), and docketed under 24-cv- 00554, i...
Indivior
© PR Newswire
25 September 2024 02:45PM
INDV Investors Have Opportunity to Lead Indivior PLC Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, Sept. 25, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Indivior PLC ("Indivior" or "the Company") (NASDAQ: INDV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. S...
Indivior
© PR Newswire
24 September 2024 11:45AM
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 1, 2024 in Indivior PLC Lawsuit - INDV
NEW YORK, Sept. 24, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Indivior PLC ("Indivior" or the "Company") (NASDAQ: INDV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover...
Indivior
© PR Newswire
23 September 2024 11:45AM
October 1, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against INDV
NEW YORK, Sept. 23, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Indivior PLC (NASDAQ: INDV). Shareholders who purchased shares of INDV during the class period listed are encouraged to cont...
Indivior
© PR Newswire
22 September 2024 06:15PM
INDV Investors Have Opportunity to Lead Indivior PLC Securities Fraud Lawsuit
NEW YORK, Sept. 22, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers and acquirers of securities of Indivior PLC (NASDAQ: INDV) between February 22, 2024 and July 8, 2024, both dates inclusive (the "Class Period"), of the important October 1, 2024 lead plaintiff deadline....
Indivior
© PR Newswire
20 September 2024 11:00PM
INDV Investors Have Opportunity to Lead Indivior PLC Securities Fraud Lawsuit
LOS ANGELES, Sept. 20, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Indivior PLC ("Indivior" or the "Company") (NASDAQ: INDV)....
Indivior
© PR Newswire
20 September 2024 11:45AM
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Indivior PLC(INDV) Shareholders
NEW YORK, Sept. 20, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Indivior PLC ("Indivior" or the "Company") (NASDAQ: INDV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover...
Indivior
© PR Newswire
19 September 2024 11:45AM
The Gross Law Firm Reminds Indivior Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 1, 2024 - INDV
NEW YORK, Sept. 19, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Indivior PLC (NASDAQ: INDV). Shareholders who purchased shares of INDV during the class period listed are encouraged to cont...
Indivior
© PR Newswire
18 September 2024 07:45PM
INDV Investors Have Opportunity to Lead Indivior PLC Securities Fraud Lawsuit
LOS ANGELES, Sept. 18, 2024 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Indivior PLC ("Indivior" or the "Company") (NASDAQ: INDV)....
Indivior
© PR Newswire
18 September 2024 02:30AM
INDV Investors Have Opportunity to Lead Indivior PLC Securities Fraud Lawsuit
NEW YORK, Sept. 17, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers and acquirers of securities of Indivior PLC (NASDAQ: INDV) between February 22, 2024 and July 8, 2024, both dates inclusive (the "Class Period"), of the important October 1, 2024 lead plaintiff deadline....
Indivior
© PR Newswire
17 September 2024 11:57PM
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Indivior PLC of Class Action Lawsuit and Upcoming Deadlines - INDV
NEW YORK, Sept. 17, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Indivior PLC ("Indivior" or the "Company") (NASDAQ: INDV) and certain officers. The class action, filed in the United States District Court for the Eastern District of Virginia (Richmond Division), and docketed under 24-cv- 00554, i...
Indivior
© PR Newswire
17 September 2024 02:30PM
Indivior PLC Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - INDV
LOS ANGELES, Sept. 17, 2024 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Indivior PLC ("Indivior" or "the Company") (NASDAQ: INDV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission....
Indivior
© PR Newswire
17 September 2024 11:45AM
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 1, 2024 in Indivior Lawsuit - INDV
NEW YORK, Sept. 17, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Indivior PLC ("Indivior" or the "Company") (NASDAQ: INDV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover...
Indivior
© PR Newswire
16 September 2024 02:15PM
INDV Investors Have Opportunity to Lead Indivior PLC Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, Sept. 16, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Indivior PLC ("Indivior" or "the Company") (NASDAQ: INDV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. S...
Indivior
© PR Newswire

The information service offers company-relevant news from leading newswire services in a compact form for a quick overview. When the detailed view is called up, further information can be accessed if required. The navigation elements in previewer mode allow you to quickly switch to the most frequently visited tool sections. From there, you can access further areas that can be used for your own research and analysis. Tip: The information platform now includes more than 50 mini-apps developed in-house.

AI First: Feel free to test the AI integration that will quickly put you on a par with financial journalists and research houses

Further information

The information presented in this section is secondary publications. The content corresponds to the source information. You can find information on the author of the news item in the detailed information of a publication. News relating to listed companies may have been created due to regulatory publication obligations, due to regular public relations work for PR or marketing reasons or by third parties against the background of investor information.

The combination of information and graphic elements contributes significantly to visual orientation and navigation through complex issues. This makes it easier to grasp, contextualize and process key content. Images, logos and other or comparable graphic and textual elements used on the information portal are used for visual navigation, are part of the original message or have illustrative purposes. All rights to these elements are held by the respective owners of the trademark or image rights. They are used without intent to infringe copyright or intellectual property rights. Image material provided via the distribution networks is treated as part of the original message and processed accordingly.

If you believe that copyright or intellectual property rights have been infringed by the presentation, please contact us immediately to clarify your concerns.